FI75183B - Foerfarande foer framstaellning av en komplement-bindande monoklonal antikropp mot maenniskans t-celler genom anvaendning av en ny hybridcellinje. - Google Patents

Foerfarande foer framstaellning av en komplement-bindande monoklonal antikropp mot maenniskans t-celler genom anvaendning av en ny hybridcellinje. Download PDF

Info

Publication number
FI75183B
FI75183B FI801342A FI801342A FI75183B FI 75183 B FI75183 B FI 75183B FI 801342 A FI801342 A FI 801342A FI 801342 A FI801342 A FI 801342A FI 75183 B FI75183 B FI 75183B
Authority
FI
Finland
Prior art keywords
cells
cell
antibody
reacts
laz
Prior art date
Application number
FI801342A
Other languages
English (en)
Finnish (fi)
Other versions
FI75183C (sv
FI801342A (fi
Inventor
Patrick Chung-Shu Kung
Gideon Goldstein
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21871750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI75183(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of FI801342A publication Critical patent/FI801342A/fi
Priority to FI844704A priority Critical patent/FI75058C/sv
Application granted granted Critical
Publication of FI75183B publication Critical patent/FI75183B/fi
Publication of FI75183C publication Critical patent/FI75183C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (2)

1. Förfarande för framställning av en monoklonal antikropp, vilken a) reagerar med praktiskt taget alla människans normala perifera T-celler och hudens T-lymfomceller, men reagerar inte med människans normala perifera B-celler, nollceller eller makro-fager, b) reagerar med cirka 5-10 % av människans normala tymo- cyter, c) reagerar med leukemiceller frän patienter med kronisk lymfoblastisk τ-celleukemi, men reagerar inte med leukemiceller frän patienter med akut lymfoblastisk T-celleukemi, akut lymfoblastisk nollcelleukemi eller kronisk lymfatisk B-celleukemi, d) reagerar svagt med människans T-cellinje HJD-1, men reagerar inte med cellinjer CEM, Laz 191 eller HM1, e) reagerar inte med människans B-cellinjer Laz 007, Laz 156, Laz 256 eller SB, som transformerats med Epstein-Barr-virus, och f) binder komplement, kännetecknat därav, att förfarandet omfattar de föl-jande stegen: man (A) framställer hybridoma ATCC CRL 8001 genom i) immunisering av möss med människans E-rosett-positiva, renade T-celler, ii) avlägsning av mjältarna frän de immuniserade mössen och framställning av en mjältcellsuspension, iii) fusionering av nämnda mjältceller med musmyelomaceller i närvaro av en fusionskatalysator, iv) utspädning och odling av de fusionerade cellerna i separata brunnar i ett medium, där fria myelomaceller inte växer, v) evaluering av supernatanten i varje brunn som innehäller ett hybridoma med avseende pä närvaro av en antikropp mot E-rosett-positiva, renade T-celler, vi) väljning och kloning av hybridoma ATCC CRL 8001, som producerar en antikropp, som binder komplement och reagerar med 24 7 5 1 83 praktiskt taget alla människans normala perifera T-celler, men inte med människans normala perifera B-celler, nollceller eller makrofager, och B) framställer den monoklonala antikroppen genom vii) odling av hybridoma ATCC CRL 8001 i ett lämpligt medium, och viii) tillvaratagande av antikroppen frän supernatanten över nämnda hybridoma.
2. Förfarande för framställning av en monoklonal antikropp, vilken a) reagerar med praktiskt taget alla människans normala perifera T-celler och hudens T-lymfomceller, men reagerar inte med människans normala perifera B-celler, nollceller eller makrofager, b) reagerar med cirka 5-10 % av människans normala tymo- cyter, c) reagerar med leukemiceller frän patienter med kronisk lymfoblastisk T-celleukemi, men reagerar inte med leukemiceller frän patienter med akut lymfoblastisk T-celleukemi, akut lymfoblastisk nollcelleukemi eller kronisk lymfatisk B-celleukemi, d) reagerar svagt med människans T-cellinje HJD-1, men reagerar inte med cellinjer CEM, Laz 101 eller HM1, e) reagerar inte med människans B-cellinjer Laz 007, Laz 256 eller SB, som transformerats med Epstein-Barr-virus, och f) binder komplement, kännetecknat därav, att förfarandet omfattar de föl-jande stegen: man (A) framställer hybridoma ATCC CRL 8001 genom i) immunisering av möss med människans E-rosett-positiva, renade T-celler, ii) avlägsning av mjältarna frän de immuniserade mössen och framställning av en mjältcellsuspension, iii) fusionering av nämnda mjältceller med musmyeloma-celler i närvaro av en fusionskatalysator, iv) utspädning och odling av de fusionerade cellerna i separata brunnar i ett medium, där fria myelomaceller inte växer, II
FI801342A 1979-04-26 1980-04-25 Förfarande för framställning av en komplement-bindande monoklonal anti kropp mot människans T-celler genom användning av en ny hybridcellinje . FI75183C (sv)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI844704A FI75058C (sv) 1979-04-26 1984-11-29 Diagnostiskt förfarande för bestämning av proportionen av T-celler i c irkulerande lymfocyter samt för påvisande av kutan-T-cellymfoma under användning av en ny komplement-bindande monoklonal antikropp.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/033,669 US4361549A (en) 1979-04-26 1979-04-26 Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US3366979 1979-04-26

Publications (3)

Publication Number Publication Date
FI801342A FI801342A (fi) 1980-10-27
FI75183B true FI75183B (fi) 1988-01-29
FI75183C FI75183C (sv) 1988-05-09

Family

ID=21871750

Family Applications (1)

Application Number Title Priority Date Filing Date
FI801342A FI75183C (sv) 1979-04-26 1980-04-25 Förfarande för framställning av en komplement-bindande monoklonal anti kropp mot människans T-celler genom användning av en ny hybridcellinje .

Country Status (22)

Country Link
US (1) US4361549A (sv)
EP (1) EP0018795B2 (sv)
JP (2) JPS55145617A (sv)
AT (1) ATE14023T1 (sv)
AU (1) AU544791B2 (sv)
CA (1) CA1182406A (sv)
DE (2) DE3070803D1 (sv)
DK (1) DK154769C (sv)
ES (1) ES8105152A1 (sv)
FI (1) FI75183C (sv)
HK (1) HK23886A (sv)
IE (1) IE50422B1 (sv)
IL (1) IL59917A (sv)
MY (1) MY8600514A (sv)
NL (1) NL930131I2 (sv)
NO (1) NO159221C (sv)
NZ (1) NZ193469A (sv)
PH (1) PH16642A (sv)
PT (1) PT71147B (sv)
SG (1) SG6686G (sv)
YU (1) YU48442B (sv)
ZA (1) ZA802525B (sv)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582797A (en) * 1980-09-25 1986-04-15 The Salk Institute For Biological Studies Monoclonal antibodies specific for human hematopoietic cell surface glycoproteins
DE3105150A1 (de) * 1981-02-12 1982-08-19 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Herstellung von anti-t-lymphozyten-globulin.
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4471056A (en) * 1982-04-02 1984-09-11 The Board Of Trustees Of The Leland Stanford Junior University Method for HLA-DR typing of total human lymphocyte sample
US4657852A (en) * 1982-04-02 1987-04-14 The Board Of Trustees Of The Leland Stanford Junior University Method for B cell typing of total human lymphocyte sample
US4511662A (en) * 1982-06-18 1985-04-16 Bio-Rad Laboratories, Inc. Simultaneous assay for T and B lymphocyte populations and subpopulations
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
US4500637A (en) * 1982-07-19 1985-02-19 The United States Of America As Represented By The Department Of Health And Human Services Prevention of graft versus host disease following bone marrow transplantation
US4714613A (en) * 1982-09-30 1987-12-22 The Albert Einstein College Of Medicine Of Yeshiva University Method of suppressing cell growth by immunotherapy
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
US4797475A (en) * 1983-05-20 1989-01-10 The Regents Of The University Of California Method and composition for isolating white cell elements
US4645738A (en) * 1983-09-30 1987-02-24 Memorial Sloan-Kettering Institute Cancer Center Method for differential diagnosis of T cell leukemias using monoclonal antibodies
US4468346A (en) * 1983-10-27 1984-08-28 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to porcine immunoglobulins
JPS60231699A (ja) * 1983-11-09 1985-11-18 Aichiken 正常及び悪性ヒト造血器細胞に対するモノクローナル抗体
US4672044A (en) * 1984-08-24 1987-06-09 Scripps Clinic & Research Foundation Murine monoclonal antibody combining site to human C3b receptor (CR1)
US4661446A (en) * 1985-02-19 1987-04-28 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies and method of immunizing therewith
US5431897A (en) * 1985-04-19 1995-07-11 Sloan-Kettering Institute For Cancer Research Method of imaging colorectal carcinoma lesion and composition for use therein
US5091178A (en) * 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4970299A (en) * 1986-07-03 1990-11-13 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies selective for prostate cancer
JPH03502280A (ja) * 1987-10-16 1991-05-30 バイオメディカル・システムズ・リミテツド Ｔ細胞系ｈｓｂ‐２およびｔ細胞性慢性リンパ性白血病（ｔ‐ｃｌｌ）細胞を加えて成長させた、正常ヒトｔおよびｂリンパ球ならびに単球と反応するマウス単クローン性抗体
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
IL92382A (en) * 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
JPH0291833U (sv) * 1988-12-29 1990-07-20
JPH0277212U (sv) * 1989-01-25 1990-06-13
AU6642390A (en) * 1989-10-27 1991-05-31 Arch Development Corporation Methods and compositions for promoting immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
JPH0420550U (sv) * 1990-06-11 1992-02-20
US5444155A (en) * 1991-09-10 1995-08-22 The Scripps Research Institute Molecules with antibody combining sites that induce asymmetry
US5250426A (en) * 1991-10-22 1993-10-05 The Scripps Research Institute Molecules with antibody combining sites that induce asymmetry
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
JP2000503003A (ja) 1995-12-22 2000-03-14 イムノメディクス，インコーポレイテッド 多段階カスケード増強ワクチンの効果を高めるための免疫接合体の使用
DE69637856D1 (en) 1996-08-30 2009-04-16 Human Genome Sciences Inc Interleukin-19.
CA2310805A1 (en) * 1997-11-24 1999-06-03 Johnson T. Wong Methods for treatment of hiv or other infections using a t cell or viral activator and anti-retroviral combination therapy
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US7678836B2 (en) * 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US8557868B2 (en) * 2000-11-04 2013-10-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions using low molecular weight amines
US20070104744A1 (en) * 2000-11-08 2007-05-10 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing forms of vitamin b
US9492582B2 (en) * 2000-11-08 2016-11-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US20060148665A1 (en) * 2000-11-08 2006-07-06 Bioconcept Laboratories Ophthalmic and contact lens solutions containing forms of vitamin b
US9308264B2 (en) 2000-11-08 2016-04-12 Fxs Ventures, Llc Ophthalmic contact lens solutions containing forms of vitamin B
US20070110782A1 (en) * 2000-11-08 2007-05-17 Fxs Ventures, Llc L-histidine in ophthalmic solutions
DK1339418T3 (da) * 2000-11-08 2009-12-14 Fxs Ventures Llc Forbedret ophthalmiske og kontaktlinseoplösninger indeholdende simple saccharider som konserverende forstærkere
ATE454157T1 (de) * 2000-11-08 2010-01-15 Fxs Ventures Llc L-histidin in ophthalmologischen lösungen
US20060127496A1 (en) * 2000-11-08 2006-06-15 Bioconcept Laboratories L-histidine in ophthalmic solutions
US7939501B2 (en) * 2003-04-15 2011-05-10 Smith Francis X Ophthalmic and contact lens solutions containing peptides as preservative
CA2542239C (en) * 2003-10-16 2014-12-30 Micromet Ag Multispecific deimmunized cd3-binders
ES2393674T3 (es) * 2003-11-14 2012-12-27 Brigham And Women's Hospital, Inc. Métodos para modular la inmunidad
SG163615A1 (en) * 2005-07-11 2010-08-30 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
JP2009544761A (ja) * 2006-06-14 2009-12-17 マクロジェニクス，インコーポレーテッド 低毒性免疫抑制モノクローナル抗体を用いて自己免疫疾患を治療する方法
US20100015142A1 (en) * 2006-12-21 2010-01-21 Macrogenics Inc. Methods for the treatment of lada and other adult- onset autoimmune using immunosuppressive monoclonal antibodies with reduced toxicity
DK3156485T3 (en) 2009-07-17 2019-01-07 Bioatla Llc At the same time, integrated selection and development of antibody / protein services and expression in production hosts
US20130078238A1 (en) 2010-04-29 2013-03-28 Hadasit Medical Research Services & Decvelopment Co. Ltd. Methods and Compositions for Treating Hepatitis with Anti-CD3 Immune Molecule Therapy
WO2012009026A2 (en) 2010-07-16 2012-01-19 Bioatla Llc Novel methods of protein evolution
JP2014500879A (ja) 2010-11-16 2014-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法
EP2658970B1 (en) 2010-12-31 2016-09-28 Bioatla LLC Express humanization of antibodies
US10670608B2 (en) 2010-12-31 2020-06-02 Bioatla, Llc Comprehensive monoclonal antibody generation
EP2817625A2 (en) 2012-02-23 2014-12-31 Stage Cell Therapeutics GmbH Chromatographic isolation of cells and other complex biological materials
MX2019001355A (es) 2012-05-10 2023-01-17 Bioatla Llc Anticuerpos monoclonales multiespecíficos.
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP3447493B1 (en) 2014-01-07 2020-05-13 Bioatla, LLC Proteins targeting orthologs
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EP3988920A1 (en) 2014-04-16 2022-04-27 Juno Therapeutics GmbH Methods, kits and apparatus for expanding a population of cells
CN107108738A (zh) 2014-07-25 2017-08-29 西托姆克斯治疗公司 抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
EP3699198A1 (en) 2014-11-17 2020-08-26 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using cd3xcd20 bispecific antibody
PT3247725T (pt) 2015-01-23 2020-10-07 Sanofi Sa Anticorpos anti-cd3, anticorpos anti-cd123 e anticorpos biespecíficos que se ligam de forma biespecífica a cd3 e/ou a cd123
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
RU2761555C2 (ru) 2015-10-22 2021-12-09 Джуно Терапьютикс Гмбх Способы, наборы, средства и устройства для трансдукции
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
DK3411398T3 (da) 2016-02-05 2024-06-24 Orionis Biosciences BV Målrettede terapeutiske midler og anvendelse heraf
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
TW201842335A (zh) 2017-04-27 2018-12-01 德商朱諾醫療公司 寡聚粒子試劑及其使用方法
SG11202104355SA (en) 2018-10-31 2021-05-28 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
EP3877054B1 (en) 2018-11-06 2023-11-01 Juno Therapeutics, Inc. Process for producing genetically engineered t cells
US20220348660A1 (en) 2019-10-02 2022-11-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of adult t-cell leukemia/lymphoma
AU2020377043A1 (en) 2019-10-30 2022-06-02 Juno Therapeutics Gmbh Cell selection and/or stimulation devices and methods of use
US20230190798A1 (en) 2020-02-12 2023-06-22 Juno Therapeutics, Inc. Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof
AU2021219764A1 (en) 2020-02-12 2022-09-01 Juno Therapeutics, Inc. BCMA-directed chimeric antigen receptor T cell compositions and methods and uses thereof
CN115697403A (zh) 2020-03-10 2023-02-03 迪赞纳生命科学公开有限公司 Il-6/il-6r抗体的组合物及其使用方法
EP4150057A2 (en) 2020-05-13 2023-03-22 Juno Therapeutics, Inc. Process for producing donor-batched cells expressing a recombinant receptor
US20230190804A1 (en) 2020-06-17 2023-06-22 Tiziana Life Sciences Plc Compositions and methods for augmenting chimeric antigen receptor (car) t cell therapies
JP2023535792A (ja) 2020-07-30 2023-08-21 ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー コロナウイルス治療のための抗ｃｄ３抗体
WO2022221767A1 (en) 2021-04-16 2022-10-20 Tiziana Life Sciences Plc Subcutaneous administration of antibodies for the treatment of disease
WO2022234009A2 (en) 2021-05-06 2022-11-10 Juno Therapeutics Gmbh Methods for stimulating and transducing t cells
AU2022365121A1 (en) 2021-10-14 2024-04-18 The Brigham And Women's Hospital, Inc. Methods of suppressing microglial activation
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023147331A1 (en) 2022-01-26 2023-08-03 Mabswitch Inc. Bispecific molecule with tunable affinity to a targetted antigen
WO2023147510A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Chromatography arrays and related methods and kits
WO2023150518A1 (en) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
WO2024161021A1 (en) 2023-02-03 2024-08-08 Juno Therapeutics Gmbh Methods for non-viral manufacturing of engineered immune cells
US20240285762A1 (en) 2023-02-28 2024-08-29 Juno Therapeutics, Inc. Cell therapy for treating systemic autoimmune diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR956062A (sv) * 1950-01-24
GB824492A (en) * 1955-10-07 1959-12-02 Frederick William Beinlich Process and apparatus for the generation of power
US3988895A (en) * 1974-01-11 1976-11-02 Itzhak Sheinbaum Power generation from hot brines
US3986362A (en) * 1975-06-13 1976-10-19 Petru Baciu Geothermal power plant with intermediate superheating and simultaneous generation of thermal and electrical energy
US4089175A (en) * 1975-06-23 1978-05-16 Occidental Petroleum Corporation Process and system for recovery of energy from geothermal brines and other water containing sources by direct contact with a working fluid below the critical pressure
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4172124A (en) * 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
BE875277A (fr) * 1979-04-02 1979-10-02 Jourdain Leon J Machine motrice
US4284412A (en) * 1979-07-13 1981-08-18 Ortho Diagnostics, Inc. Method and apparatus for automated identification and enumeration of specified blood cell subclasses

Also Published As

Publication number Publication date
YU48442B (sh) 1998-07-10
AU544791B2 (en) 1985-06-13
EP0018795B1 (en) 1985-06-26
ES490944A0 (es) 1981-05-16
FI75183C (sv) 1988-05-09
NZ193469A (en) 1984-07-06
HK23886A (en) 1986-04-11
MY8600514A (en) 1986-12-31
DK180380A (da) 1980-10-27
JPS6362520B2 (sv) 1988-12-02
SG6686G (en) 1986-08-01
PT71147B (en) 1981-08-11
NL930131I2 (nl) 1998-07-01
DK154769B (da) 1988-12-19
IL59917A (en) 1983-12-30
EP0018795A3 (en) 1981-01-07
PH16642A (en) 1983-12-06
IL59917A0 (en) 1980-06-30
DE18795T1 (de) 1984-07-19
CA1182406A (en) 1985-02-12
ATE14023T1 (de) 1985-07-15
IE50422B1 (en) 1986-04-16
DK154769C (da) 1989-06-19
EP0018795B2 (en) 1999-04-07
NL930131I1 (nl) 1993-11-01
JPH0198478A (ja) 1989-04-17
JPS55145617A (en) 1980-11-13
NO159221B (no) 1988-08-29
ZA802525B (en) 1981-12-30
EP0018795A2 (en) 1980-11-12
JPH0159868B2 (sv) 1989-12-20
NO801214L (no) 1980-10-27
ES8105152A1 (es) 1981-05-16
IE800840L (en) 1980-10-24
YU114680A (en) 1984-02-29
NO159221C (no) 1988-12-07
DE3070803D1 (en) 1985-08-01
PT71147A (en) 1980-05-01
FI801342A (fi) 1980-10-27
US4361549A (en) 1982-11-30
AU5775780A (en) 1980-10-30

Similar Documents

Publication Publication Date Title
FI75183B (fi) Foerfarande foer framstaellning av en komplement-bindande monoklonal antikropp mot maenniskans t-celler genom anvaendning av en ny hybridcellinje.
FI75184C (sv) Förfarande för framställning av en monoklonal antikropp mot mänskliga T-cellers antigener med en ny hybridcellinje.
FI75363C (sv) Förfarande för framställning av en monoklonal antikropp mot människans hjälpar-T-celler, medelst en ny hybridcellinje.
FI75365C (sv) Förfarande för framställning av monoklonal antikropp till mänsklig pro tymocytantigen medelst deras hybridcellinje.
FI75362B (fi) Foerfarande foer framstaellning av en monoklonal antikropp mot maenniskans t-celler, medelst en ny hybridcellinje.
US4515893A (en) Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
FI75366C (sv) Förfarande för framställning av en komplement-fixerande monoklonal ant ikropp mot mänskliga supressor-T-celler medelst en hybridcellinje.
US4658019A (en) Complement-fixing monoclonal antibody to human T cells
FI75600C (sv) Förfarande för framställning av en monoklonal antikropp mot en mänskli g monocytantigen medelst en ny hybridcellinje.
FI75364B (fi) Foerfarande foer framstaellning av en monoklonal antikropp foer maenskliga cytotoxiska och suppressor-t-celler medelst en ny hybridcellinje.
FI75598B (fi) Foerfarande foer framstaellning av en monoklonal antikropp mot en maensklig tymocytantigen medelst en ny hybridcellinje.
US4654210A (en) Methods and compositions using complement fixing monoclonal antibody to human T cells
EP0030814A2 (en) Hybrid cell line for producing monoclonal antibody to a human early thymocyte antigen, antibody, method of preparation of this antibody, diagnostic and therapeutic uses and pharmaceutical compositions comprising this antibody
FI75058C (sv) Diagnostiskt förfarande för bestämning av proportionen av T-celler i c irkulerande lymfocyter samt för påvisande av kutan-T-cellymfoma under användning av en ny komplement-bindande monoklonal antikropp.
SI8011146A8 (sl) Postopek za pridobivanje monoklonalnega protitelesa okt3
HRP940824A2 (en) Hybrid cell line for producing monoclonal antibody to a human prothymocyte antigen, antibody, and methods

Legal Events

Date Code Title Description
MA Patent expired

Owner name: ORTHO PHARMACEUTICAL CORPORATION